Search This Board: 
Created: 06/18/2013 06:52:08 PM - Followers: 12 - Board type: Free - Posts Today: 0

Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company discovering and developing novel monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

The Company’s work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Prothena’s novel cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). Our strategy is to identify antibody candidates for clinical development by applying Prothena’s extensive expertise in generating novel therapeutic antibodies and working with collaborators having expertise in specific animal models of disease. Our lead program, NEOD001, is in Phase 1, and we anticipate moving one or more of our product candidates into clinical development each year in 2014 and 2015.

Prothena has attracted an elite team with a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. The team brings this heritage to Prothena with the vision of continuing to create and develop novel antibody-based therapies that benefit a diverse population of patients. We also have assembled a globally recognized Scientific Advisory Board with a broad spectrum of academic and industry experience in the fields of neuroscience and immunotherapy.

Prior to December 2012, the Prothena Business operated as part of Elan Corporation, plc (Elan), not as a separate stand-alone entity. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform, including Neotope Biosciences Limited and Onclave Therapeutics Limited, each former wholly owned subsidiaries of Elan. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The NASDAQ Global Market under the symbol “PRTA” on December 21, 2012.

Prothena is targeting proteins in novel ways to resolve unmet medical needs in patients.

The history of Prothena began with Athena Neurosciences, which was founded in 1986.  Since Athena’s inception, the company’s scientists consistently have made significant discoveries that have advanced our understanding of the biology of Alzheimer’s disease.  Particularly impactful were the fundamental breakthroughs we made in elucidating the roles amyloid, gamma secretase, and beta secretase play in the disease.  These discoveries led to the development of a drug discovery and development organization, which generated multiple clinical candidates that have been and continue to be tested in Alzheimer’s disease patients. 

These same scientists also pioneered significant scientific discoveries with cell adhesion molecules, leading to the discovery and development of Tysabri® (natalizumab), which is now approved for use in relapsing forms of multiple sclerosis and sold by Biogen Idec. 

Athena was acquired by Elan Corporation in 1996, and its discovery and development activities were incorporated into Elan Pharmaceuticals at that time.  In December 2012, Elan completed the successful demerger of its discovery and early development efforts resulting in Prothena, which is an independent publicly traded company with a strong pipeline of discovery programs, early stage clinical assets and preeminent scientists.

Instead of focusing on a specific therapeutic indication or platform technology, Prothena focuses on what we are best at – elucidating the contribution of protein misfolding and cell trafficking dysfunction to disease states and developing therapeutic approaches that interact in novel ways with proteins.  Today, we are building a broad pipeline of compounds that could deliver the next generation of breakthrough therapies by drawing from our vast knowledge of in these areas of biology.


Amyloidosis is a term used for a variety of conditions that result when a normally soluble protein misfolds and accumulates, which can become toxic to organ tissue.  Amyloidoses can affect any organ in the body, including the brain and peripheral organs.  For example, the misfolding and aggregation of the amyloid beta (Aβ) peptide leads to a build-up of amyloid protein in the brain, which most scientists believe is the primary cause of Alzheimer’s disease.  The scientific discoveries the team has made in Alzheimer’s disease led to the discovery of potential methods for intervening in the amyloidosis that occurs in other parts of the body.  Amyloidogenic proteins including amyloid light chain (AL), amyloid A (AA) and transthyretin (TTR) are believed to cause toxicity in peripheral organs under pathological conditions.  Collectively, the peripheral diseases caused by these proteins are known as systemic amyloidoses. 

Our goal is to develop new product candidates that target these misfolded proteins, and our lead candidate, NEO001, has begun Phase 1 clinical testing in AL amyloidosis patients.

Parkinson’s disease

Synucleins are a family of proteins, of which there are three known members: α-synuclein, β-synuclein, and ?-synuclein. The α- and β-synuclein proteins are found primarily in brain tissue.  The ?-synuclein protein is found primarily in the peripheral nervous system and retina, as well as several tumor types.  While the role synuclein proteins play in normal cellular functioning has not been fully determined, there are data to suggest that synucleins assist with the stability of cellular membranes and/or their turnover. 

Mutations and changes in the levels of α-synuclein have been associated with multiple neurodegenerative illnesses, including Parkinson’s disease.  This protein is also a prominent component of Lewy bodies and Lewy neurites (abnormal protein clusters on the inside of neurons). Lewy bodies and Lewy neurites are pathological hallmarks of several neurological disorders collectively known as synucleinopathies.  Synucleinopathies include Parkinson’s disease; dementia with Lewy bodies; multiple system atrophy; and certain other neurological disorders.  In synucleinopathies, the α-synuclein protein is believed to misfold and aggregate to form the protein structures that are thought to contribute to the pathology of the disease. 

Current treatment options for Parkinson’s disease and other synucleinopathies focus on providing symptomatic benefit; our goal is to slow the progression of disease.  To achieve this, we have developed monoclonal antibodies intended to slow or reduce the neurodegeneration associated with α-synuclein misfolding and/or its transmission.  The lead candidate in this portfolio, PRX002, is expected to begin Phase 1 testing in 2014.


Our scientists have maintained an interest in the biology of T-cell migration.  In other words, determining how T-cells leave the circulatory system by attaching and migrating across blood vessel walls.  We have made several fundamental scientific contributions that further our understanding of cell adhesion molecules and their role in allowing particularly pathogenic cells and proteins to transfer out of the circulatory system and into tissue sites where they initiate the damage associated with a variety of autoimmune diseases.  These initial discoveries led to the development of Tysabri® (natalizumab), a highly effective drug that prevents inflammatory cells from entering the brain during periods of multiple sclerosis relapse, which is marketed by Biogen Idec.

There is a significant amount of literature suggesting Th17 cells are the primary cause of a variety of inflammatory diseases.  Since Th17 cells represent a relatively small proportion of the overall T-cell population, we have focused on targeting these cells specifically in order to leave the majority of immune function intact.    

Our approach is designed to prevent Th17 cells from leaving the blood vessels and infiltrating the tissue by blocking the interaction of a key cell adhesion protein, explicitly expressed on the surface of Th17 cells, with its binding partner on the blood vessel.  As such, our approach differs with some other approaches that have focused directly on targeting individual cytokines released by Th17 cells, particularly IL-17.  The same cell adhesion molecule is called the melanoma cell adhesion molecule (MCAM).  MCAM appears to be critical for Th17 migration and has been reported to be upregulated on a variety of metastatic tumor cells that may utilize a similar molecular approach to spread to new tissue sites.  We believe there is enormous potential in conducting discovery and development work in Th17-mediated inflammatory diseases and cancer.  We are testing a portfolio of monoclonal antibodies that we have developed to selectively block MCAM-mediated cell adhesion.  We have selected a lead candidate for clinical development and anticipate initiating Phase 1 clinical testing in 2015.

Our Discovery team continues to deliver new approaches to Prothena’s pipeline in a number of therapeutic areas as we progress our lead programs clinically.  We are confident the important discoveries made to date and continued future innovation will ensure a profound impact on human health for decades to come.


Prothena Corporation is a clinical-stage biotechnology company with a portfolio of novel monoclonal antibodies that may offer new treatments for diseases associated with protein misfolding or cell adhesion. 

Prothena’s research and development pipeline includes three lead therapeutic antibody programs that we are advancing aggressively: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 for the treatment of Parkinson’s disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers.  NEOD001 is in Phase 1 development, and in both 2014 and 2015, we anticipate moving one or more of our other product candidates into the clinic.

Prothena’s pipeline includes several discovery-stage programs studying antibodies that may offer potential treatments for Alzheimer’s disease and Type 2 Diabetes.  The Company continues to generate additional novel antibodies against other targets involved in protein misfolding and cell adhesion. 

Prothena employs three distinct strategies to ensure we are allocating our resources towards the appropriate antibody and target disease, potentially increasing the likelihood each compound will complete Phase 3 development successfully.  We leverage our insight into the pathology of diseases involving protein misfolding and cell adhesion to employ biomarker endpoints in order to detect signals of clinical efficacy early in the clinical development process.  We collaborate with scientists who are recognized as experts in our disease areas of interest to test and characterize our potential therapeutic antibody candidates.  We seek feedback and guidance on our programs from leading clinical experts.  We believe these strategies give us the opportunity to make the most educated decisions about our compounds throughout the development process.

Management Team

Prothena Corporation has attracted an elite team with an extensive track record in discovering and developing therapeutics that have become the leading commercial products in their respective therapeutic categories. The team brings this heritage to Prothena with the vision of continuing to create and develop novel antibody-based therapies that benefit a diverse population of patients.

Dr. Dale Schenk, Chief Executive Officer of Prothena, was most recently Chief Scientific Officer and Executive Vice President at Elan Pharmaceuticals where he provided the leadership and scientific direction for Elan’s research and development programs.  Prior to joining Elan, Dr. Schenk was a founding scientist of Athena Neurosciences, which was acquired by Elan Pharmaceuticals. Dr. Schenk has pioneered the immunotherapeutic approach for the treatment of amyloidosis, as exemplified for Alzheimer’s disease. Dr. Schenk’s work in this area, as well as in early detection, testing and other pathways to the disease, has led to the most advanced potential treatment approaches for Alzheimer’s disease.  Dr. Schenk earned his BA and PhD in Pharmacology and Physiology from the University of California, San Diego.

Dr. Gene Kinney, Head of Research and Development, was most recently Senior Vice President, Pharmacological Sciences at Elan Pharmaceuticals and head of Nonclinical Research at Janssen Alzheimer Immunotherapy R&D.  Prior to joining Elan, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories.  During his tenure at Merck, Dr. Kinney contributed to the strategic direction and oversight of drug discovery activities and led a number of nonclinical discovery and clinical development programs targeted for the treatment of neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s diseases) and psychiatric conditions (e.g., schizophrenia and depression).  Dr. Kinney also has held positions at Bristol-Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences.  Dr. Kinney earned his BA from Bloomsburg University and his MA and PhD from Florida Atlantic University.

Dr. Nickerson, Head of Corporate and Business Development of Prothena, was most recently Vice President and Head of Business Development at Elan Pharmaceuticals.  During her tenure at Elan, Dr. Nickerson was responsible for opportunity evaluation, diligence, negotiations and contracting for Elan external opportunities.  Dr. Nickerson established a broad network of collaborations for Elan with academic investigators, not-for-profit disease-focused foundations and industry collaborators.  She has led efforts to build Elan’s pipeline of products for neurodegenerative disease, including license of ELND005, which currently is in Phase 2 clinical trials for bipolar disorder and agitation and aggression in Alzheimer’s disease. She was instrumental in establishing Neotope Biosciences and served as Head of Business Operations for Neotope from 2010 until 2012.  Dr. Nickerson previously was a Senior Scientist at Celera Genomics (Axys Pharmaceuticals) from 2000 to 2002 where she led preclinical programs developing novel therapeutics for oncology.  Dr. Nickerson earned her BSc and PhD in Experimental Medicine from McGill University and her MBA from the University of California, Berkeley Haas School of Business.

Mr. Nguyen, Chief Financial Officer, has 15 years of finance experience in the healthcare, banking and private equity industries.  Prior to joining Prothena, he held management positions at Somaxon Pharmaceuticals, Inc., including Senior Vice President, Vice President, Chief Financial Officer, and Investor Relations, until its sale in 2013.  Previously, Mr. Nguyen was Vice President, Chief Financial Officer and Investor Relations at Metabasis Therapeutics, Inc., until its sale in 2010.  Before entering the biotech industry, Mr. Nguyen was a vice president in the Healthcare Investment Banking group at Citi Global Markets, Inc., and served in healthcare investment banking at Lehman Brothers, Inc.  Mr. Nguyen has a BA from Claremont McKenna College and an MBA from UCLA Anderson School of Management.

Dr. Koller, Chief Medical Officer, is a board-certified neurologist with more than 20 years of experience in the life sciences industry, developing small molecules and biologic therapeutics for a diverse array of indications. Prior to joining Prothena, Dr. Koller served as Chief Medical Officer at Sonexa Therapeutics. Previously, Dr. Koller held clinical development roles and leadership positions at several life sciences companies, including Athena Neurosciences, Elan Pharmaceuticals, Syntex Pharmaceuticals and Wyeth Pharmaceuticals. Dr. Koller has extensive expertise in clinical trial design, having been involved in the clinical development of numerous INDs and NDAs targeting a broad array of indications, including Alzheimer's disease, multiple sclerosis, cervical dystonia, pain, epilepsy, migraine, stroke, anxiety, and depression. Dr. Koller has a BA from Franklin and Marshall College, an MPH with an emphasis in epidemiology from the University of Texas at Houston and his MD from the University of Maryland, Baltimore. Dr. Koller completed fellowship training in neuromuscular diseases at the University of Southern California.


PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#100 for save some unrelated infor. name 03/27/2021 12:10:15 PM
#99 UP OVER 8% TODAY 2020trader 02/16/2021 10:51:17 PM
#98 COULD BREAK $30 2020trader 02/13/2021 01:18:04 AM
#97 BREAKING NEWS: $PRTA Prothena Reports Third Quarter 2020 whytestocks 11/04/2020 04:15:30 PM
#96 JUST IN: $PRTA Prothena Announces Presentations on Two whytestocks 11/04/2020 12:00:26 PM
#95 See what kind of reaction we get Today Lenard 02/13/2020 01:14:09 AM
#94 * * $PRTA Video Chart 12-20-2019 * * ClayTrader 12/20/2019 05:51:51 PM
#93 Looks like more profit taking PennyStock Alert 09/16/2019 09:02:35 AM
#92 Nice bouncer this PRTA! Took it from girlfriend 04/26/2018 02:36:56 PM
#91 No need to force a trade. if $10 FairviewInvestor 04/23/2018 10:29:27 AM
#90 Now the Question: What's it worth. Is this FairviewInvestor 04/23/2018 10:26:31 AM
#89 Dodged a bullet.. had to check a few FairviewInvestor 04/23/2018 10:25:42 AM
#88 $PRTA - Prothena Announces Global Neuroscience Research & MinnieM 03/21/2018 08:23:16 PM
#87 Always belonged in the $40s... FairviewInvestor 01/29/2018 07:51:00 PM
#86 Cantor Fitz buy rating yesterday. FairviewInvestor 12/22/2017 03:44:05 AM
#85 Long Slide and Price Targets double from here, FairviewInvestor 12/22/2017 03:42:23 AM
#84 Still trying to form a base but belongs FairviewInvestor 12/22/2017 02:26:46 AM
#83 bought in $36.63 FairviewInvestor 12/22/2017 02:26:24 AM
#82 Prothena Corp $PRTA valuation models imply nice upside ValueInvestor15 02/14/2017 08:13:45 AM
#81 fast and steady profit scan PRTA bullish 59.97 stocktrademan 09/30/2016 04:34:49 PM
#80 $PRTA recent news/filings stocktrademan 12/17/2015 01:49:50 PM
#79 PRX002 - Excellent single dose results released today djpope 06/17/2015 09:52:44 AM
#78 $PRTA recent news/filings stocktrademan 05/29/2015 02:47:36 PM
#77 Prothena Announces Pricing of Public Offering of 3,300,000 KingDMC 04/08/2015 07:20:38 AM
#74 New paid pump out today in my email, Joey Rosa 03/24/2015 09:31:04 AM
#73 Best of luck. All i know is im Telianaire 03/23/2015 04:15:34 PM
#72 READ #61 MONEYMADE 03/23/2015 01:55:13 PM
#71 Huge reversal today Wanka 03/23/2015 12:16:29 PM
#70 Just make sure you're here when it makes KingDMC 03/23/2015 12:00:46 PM
#68 Been a DUKE fan forever. > also they crudeoil24 03/23/2015 10:13:47 AM
#67 F Duke I hate them. I can't talk KingDMC 03/23/2015 09:40:12 AM
#66 Fantastic freshman players.... Okafor, Jones, Winslow! crudeoil24 03/23/2015 09:06:22 AM
#65 DUKE!!! My whole family went to DUKE!! Blue Telianaire 03/23/2015 09:04:56 AM
#64 Glad you had fun! ... My DUKE team crudeoil24 03/23/2015 09:04:02 AM
#63 Told you! BEARISH. Just saying. This weekend I Telianaire 03/23/2015 09:00:58 AM
#62 Yup! Looks like more profit taking. crudeoil24 03/23/2015 08:32:28 AM
#61 $35 <MONDAY> MONEYMADE 03/22/2015 09:37:34 PM
#60 Yeah. Sounds really good. Crazy low float and Wanka 03/21/2015 12:26:11 AM
#59 CEO was on MAD MONEY! crudeoil24 03/20/2015 10:09:18 PM
#58 Getting a pump by cramerica. This thing prolly Wanka 03/20/2015 06:40:47 PM
#57 Nice! KingDMC 03/20/2015 04:17:34 PM
#55 38.61 close. & up in AH! crudeoil24 03/20/2015 04:01:03 PM
#52 Solid day here! I just added another 550 shares. crudeoil24 03/20/2015 03:53:28 PM
#51 Oh is that why i'm counting my money? Telianaire 03/20/2015 03:53:23 PM
#50 Tutes, mutual funds, pensions, etc > BUYING !!!!! crudeoil24 03/20/2015 03:51:42 PM
#49 I don't even pay them any mind. To KingDMC 03/20/2015 03:51:39 PM
#48 LMAO! Folks that are shorting are clueless and crudeoil24 03/20/2015 03:50:16 PM
#47 With HUGE sell volume and small buy volume Telianaire 03/20/2015 01:36:07 PM
#46 Lol Actually Ive always been a bull far Telianaire 03/20/2015 01:25:31 PM
#45 Another troll. 12 post history guy magically shorted KingDMC 03/20/2015 01:23:04 PM
Post Subject